ESTRO 2024 - Abstract Book

S1519

Clinical - Lower GI

ESTRO 2024

References:

1. Bahadoer RR, Dijkstra EA, van Etten B, et al.. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:29–42. 2. Conroy T, Bosset JF, Etienne PL, et al.. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCERPRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:702–15.

1571

Digital Poster

Ten-year experience of palliative radiotherapy in patients with non-operable rectal cancer

Joan Lozano, Esther Rubio, Montserrat Colomer, Josep Maria Solé

Consorci Sanitari de Terrassa, Radiation Oncology, Terrassa (Catalonia), Spain

Purpose/Objective:

Many older patients with rectal cancer were not candidates for surgical resection because advanced , comorbidities, or multiple synchronous metastases. In this scenario only comfort measures or different palliative radiotherapy regimens are applied, from single doses to treatments lasting several weeks. The aim of this work is to describe the results of our palliative radiotherapy protocol in patients with non-operable rectal cancer

Material/Methods:

Data were collected from medical records. Patients with rectal cancer who were not candidates for surgical resection were immobilized in prone or supine position and full bladder . Three-dimensional radiotherapy or VMAT was planned to deliver to the primary tumor and the enlarged pelvic nodes 39-45Gy in 13-15 sessions of 3Gy in 17-19 days. Symptomatic response 2 months after the end of treatment has been measured for pain and bleeding and acute toxicity were reported according to CTCAQv4.0 scale

Results:

From March 2013 to September 2023, 60 patients with a mean age of 83.1 years (39-94) were treated according to the protocol described above. Three patients died during radiotherapy and 2 patients died 9 and 15 days after completing radiotherapy and were not included in the analysis. The improvement or resolution of symptoms was 98.2% (54/55) for pain and 94.54% (52/55) for bleeding. No patient required a colostomy during the two months after radiotherapy. Grade 1 or 2 acute toxicity was (genitourinary) 21.8% (12/55) and (gastrointestinal) 60% (33/55), with no grade 3 or 4 toxicities

Conclusion: